A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder

被引：0
|
作者：
Phiri, Kelesitse [1 ]
Hallas, Jesper [2 ]
Linder, Marie [3 ]
Margulis, Andrea [4 ]
Suehs, Brandon [5 ]
Arana, Alejandro [4 ]
Bahmanyar, Shahram [3 ]
Enger, Cheryl [1 ]
Horter, Libby [5 ]
Odsbu, Ingvild [3 ]
Olesen, Morten [2 ]
Perez-Gutthann, Susana [4 ]
Kristiansen, Nina Sahlertz [2 ]
Appenteng, Kwame [6 ]
de Vogel, Stefan [7 ]
Seeger, John [1 ]
机构：
[1] Optum, Boston, MA USA
[2] Univ Southern Denmark, Odense, Denmark
[3] Karolinska Inst, Stockholm, Sweden
[4] RTI Hlth Solut, Barcelona, Spain
[5] Humana Healthcare Res, Louisville, KY USA
[6] Astellas Pharma US, Northbrook, IL USA
[7] Astellas Pharma BV, Leiden, Netherlands
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4352
引用
收藏
页码：465 / 465
页数：1
相关论文
共 50 条
  • [41] Use of mirabegron in treating overactive bladder
    Alka A. Bhide
    G. Alessandro Digesu
    Ruwan Fernando
    Vik Khullar
    International Urogynecology Journal, 2012, 23 : 1345 - 1348
  • [42] Value of Mirabegron in the Treatment of overactive Bladder
    Schneider, M. H.
    Struck, J. P.
    UROLOGE, 2019, 58 (04): : 432 - 433
  • [43] Antimuscarinic drugs to treat overactive bladder
    Robinson, Dudley
    Cardozo, Linda
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [44] Use of mirabegron in treating overactive bladder
    Bhide, Alka A.
    Digesu, G. Alessandro
    Fernando, Ruwan
    Khullar, Vik
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2012, 23 (10) : 1345 - 1348
  • [45] Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients
    Wang, Chung-Cheng
    Kuo, Hann-Chorng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (01) : 279 - 284
  • [46] Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder
    Blais, Anne-Sophie
    Nadeau, Genevieve
    Moore, Katherine
    Genois, Lucie
    Bolduc, Stephane
    EUROPEAN UROLOGY, 2016, 70 (01) : 9 - 13
  • [47] The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis
    Chapple, Christopher R.
    Khullar, Vik
    Gabriel, Zahava
    Muston, Dominic
    Bitoun, Caty Ebel
    Weinstein, David
    EUROPEAN UROLOGY, 2008, 54 (03) : 543 - 562
  • [48] A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
    Kumar, Shailendra
    Tiwari, Vidushi
    Chaurasia, Dileep K.
    Kumar, Sudheer
    Mishra, Shirish
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [49] Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
    Carlson, Kevin V.
    Rovner, Eric S.
    Nair, Kavita V.
    Deal, Anna S.
    Kristy, Rita M.
    Schermer, Carol R.
    ADVANCES IN THERAPY, 2019, 36 (08) : 1906 - 1921
  • [50] Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
    Kevin V. Carlson
    Eric S. Rovner
    Kavita V. Nair
    Anna S. Deal
    Rita M. Kristy
    Carol R. Schermer
    Advances in Therapy, 2019, 36 : 1906 - 1921
12345